Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.88 USD | -1.30% | +4.42% | -14.86% |
09/05 | Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
09/05 | Transcript : Intellia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.86% | 252.96Cr | |
+31.16% | 4.95TCr | |
+1.13% | 4.26TCr | |
+49.05% | 4.25TCr | |
-5.26% | 2.91TCr | |
+12.66% | 2.66TCr | |
-23.80% | 1.86TCr | |
+7.25% | 1.32TCr | |
+31.42% | 1.25TCr | |
+23.06% | 1.21TCr |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- JPMorgan Cuts Intellia Therapeutics' Price Target to $79 From $82, Keeps Overweight Rating